Navigation Links
World Health Day is April 7 with a Focus on Antibiotic Resistance
Date:4/4/2011

SAN DIEGO, April 4, 2011 /PRNewswire/ -- Antibiotics are among the most important advances in human health, but their use and misuse over the past 70 years have increased the number and types of microorganisms resistant to antibiotics – resulting in deaths, greater suffering and disability, and higher healthcare costs. For World Health Day 2011, the World Health Organization will call on governments and stakeholders to implement the policies and practices needed to prevent and counter the emergence of highly resistant microorganisms. The challenge posed to the pharmaceutical and biotechnology industries is loud and clear – only seven new antibiotics have been introduced since 2003. A press conference on April 7 will feature innovators in antibiotic research and development from industry and academia that are making strides to combat this problem.

WHAT:

Press Conference: Innovation in Antibiotics; Medicine for the Next Wave of Bacterial Infections

WHO:

Jeffrey Stein, Ph.D., President and CEO, Trius Therapeutics

Trius is focusing on the development of innovative antibiotics for life-threatening infections. Trius is in the final stage of clinical development for torezolid phosphate, a next generation antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including those caused by methicillin-resistant Staphylococcus aureus (MRSA).Trius has worked closely with FDA to define a path to market approval for antibiotics that are fast acting and with low acquisition of microbial resistance.

Daniel Burgess, President and CEO, Mpex Pharmaceuticals

Mpex is in the final stage of clinical testing of a proprietary inhalable formulation of levofloxacin for the treatment of microbial infections in patients with cystic fibrosis. The company's mission is to develop important new therapies to combat the growing issue of antibiotic resistance.

Andrei Osterman, Ph.D., Associate Professor Bioinformatics and Systems Biology, Sanford-Burnham Medical Research Institute

Dr. Osterman's research focuses on discovering the molecular mechanisms of disease, the true starting point for understanding what contributes to bacterial resistance. Bacteria are devilishly smart and have adapted to the weapons the pharmaceutical industry has created to fight them. Dr. Osterman and his colleagues are looking for the molecular weaknesses that we can exploit to attack resistant bacteria, with an eye towards translating lab discoveries into treatments.

Joe Panetta, President and CEO, BIOCOM

BIOCOM is the largest regional life science association in the world and represents more than 550 member companies in Southern California.

WHEN: Thursday, April 7, 2011 at 2:00 p.m. – 3:00 p.m. Pacific Time

WHERE: Sanford Children's Health Research Center, Sanford-Burnham Medical Research Institute, 10905 Road to the Cure, San Diego, CA 92121 or via webcast http://investor.triusrx.com/events.cfm.

RSVP:
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com

Organized by Canale Communications


'/>"/>
SOURCE Canale Communications
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... 17, 2017  Bayer announced today that the latest ... presented at the 53 rd Annual Meeting of ... June 2-6 in Chicago . ... prostate, colorectal, liver and thyroid cancers, as well as ... II CHRONOS-1 trial of copanlisib in patients with relapsed ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the impact ... the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and ... Walter. Walter and Jane have three adult children and a granddaughter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives ... hospital employees, and town officials to celebrate the grand opening of the 87,000 ... Rendina as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... management and interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) ... web-based, scalable and secure cloud platform for medical image management. At the core ...
(Date:5/24/2017)... Cincinnati, OH (PRWEB) , ... May 24, 2017 , ... ... discreet and comfortable ClearCorrect orthodontics, with or without a referral. Dr. Kejriwal ... is why she offers convenient, clear braces in Cincinnati, OH. Patients no longer need ...
Breaking Medicine News(10 mins):